




RealRate

PHARMACEUTICAL 2016

Anixa Biosciences Inc
Rank 165 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Anixa Biosciences Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 1.4% points below the market average of 263%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	6,896	Assets	9,336
Cost of Goods Sold	0	Liabilities	4,282
Intangible Assets	0	Expenses	10,652
Liabilities, Current	594	Revenues	9,255
Liabilities, Non-Current	0	Stockholders Equity	5,054
Other Assets	2,396	Net Income	-1,379
Other Compr. Net Income	0	Comprehensive Net Income	-1,379
Other Expenses	4,426	BaseVar	16,771
Other Liabilities	3,688	ECR before LimitedLiability	142%
Other Net Income	18	Economic Capital Ratio	262%
Other Revenues	9,255		
Property and Equipment	43		
Research and Development	0		
Selling, General and Administrative Expense	6,226		